Highlights,Vertex, Inc. reached a new twelve-month low amid broader market dynamics.,The firm posted growth in compared to ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Vertex Pharmaceuticals' stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into advanced testing. Shares slid 14% to $407.30.

Vertex Pharmaceuticals swung to a profit and logged higher sales in the second quarter, as more people used its cystic-fibrosis drug and the biotechnology company began rolling out new therapies.

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...